Year : 2008 Ganciclovir / valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation
暂无分享,去创建一个
R. Speich | D. Michel | T. Mertens | W. Weder | C. Chmiel | A. Boehler | M. Hofer
[1] H. Ulmer,et al. Combined CMV Prophylaxis Improves Outcome and Reduces the Risk for Bronchiolitis Obliterans Syndrome (BOS) after Lung Transplantation , 2006, Transplantation.
[2] Barbara Alexander,et al. Pharmacokinetic Profile of Ganciclovir After its Oral Administration and From its Prodrug, Valganciclovir, in Solid Organ Transplant Recipients , 2005, Clinical pharmacokinetics.
[3] J. Preiksaitis,et al. A Trial of Valganciclovir Prophylaxis for Cytomegalovirus Prevention in Lung Transplant Recipients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[4] S. Charman,et al. Extended ganciclovir prophylaxis in lung transplantation. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[5] M. Zamora,et al. Following Universal Prophylaxis with Intravenous Ganciclovir and Cytomegalovirus Immune Globulin, Valganciclovir is Safe and Effective for Prevention of CMV Infection Following Lung Transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[6] M. Steele,et al. Delay of CMV infection in high‐risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir , 2004, Clinical transplantation.
[7] T. Hibi,et al. Clinical significance of cytomegalovirus ( CMV ) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation , 2004 .
[8] D. McGiffin,et al. Combination Prophylaxis with Ganciclovir and Cytomegalovirus (CMV) Immune Globulin After Lung Transplantation: Effective CMV Prevention Following Daclizumab Induction , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[9] Marshall Hertz,et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[10] S. Gautam,et al. Prevention of cytomegalovirus infection and disease after lung transplantation: results using a unique regimen employing delayed ganciclovir. , 2002, Chest.
[11] S. Chou,et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. , 2002, The Journal of infectious diseases.
[12] R. Speich,et al. Improved results after lung transplantation--analysis of factors. , 2001, Swiss medical weekly.
[13] G. Raghu,et al. Comparison of the efficacy and cost effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[14] R. Speich,et al. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation. , 1999, Transplantation.
[15] R. Bolman,et al. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[16] S. Mattila,et al. Ganciclovir prophylaxis after lung and heart–lung transplantation , 1998 .
[17] A. Mehta,et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] G. Berry,et al. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[19] R. Speich,et al. Prospective study of the value of transbronchial lung biopsy after lung transplantation. , 1996, The European respiratory journal.
[20] G. Raghu,et al. EFFICACY OF A 6‐WEEK PROPHYLACTIC GANCICLOVIR REGIMEN AND THE ROLE OF SERIAL CYTOMEGALOVIRUS ANTIBODY TESTING IN LUNG TRANSPLANT RECIPIENTS , 1995, Transplantation.
[21] B. Griffith,et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. , 1994, American journal of respiratory and critical care medicine.
[22] E. Spitznagel,et al. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group. , 1993, The American review of respiratory disease.
[23] B. Griffith,et al. Ganciclovir prophylaxis for cytomegalovirus infections in pulmonary allograft recipients. , 1992, The American review of respiratory disease.
[24] J. Cooper,et al. Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants. , 1992, The Journal of infectious diseases.
[25] J. Scott,et al. Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations, and response to treatment. , 1991, The Journal of infectious diseases.
[26] B. Griffith,et al. Cytomegalovirus infection and survival in lung transplant recipients. , 1991, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[27] G. Patterson,et al. Cytomegalovirus infection in isolated lung transplantations. , 1991, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.